InVivo Therapeutics Corp. appointed Sean Moran as its first CFO.
Moran was previously CFO and vice president of business development at Brookline, Mass.-based Orban Biotech.
He also operates I-CFO LLC, a provider of CFO and capital advisory services to the management of start-ups and emerging companies, according to his LinkedIn profile.
Moran’s arrival comes as Cambridge, Mass.-based InVivo is planning to go public through a so-called reverse merger, according to the The Boston Globe. CEO Frank Reynolds told the newspaper he is attempting to raise about $5 million.
The company, which has already raised $5 million from investors, last year won a $500,000 “accelerator” loan from the Mass. Life Sciences Center.
InVivo touted Moran’s finance expertise at both public and private companies in a press release announcing his arrival.
"Moran has successfully raised capital and has extensive experience in corporate finance, mergers and acquisitions, investor and Wall Street relations and SEC reporting," according to a press release. Moran also founded Anika Therapeutics and "helped to take the company public through an IPO," according to InVivo.
That company, which is developing a biopolymer scaffolding device for the treatment of spinal cord injuries, promoted then-director of research & development Christopher Pritchard to the role of chief science officer two weeks ago.
Telephone calls to Reynolds and emails to the company were not returned.
